Irritable bowel syndrome with constipation: a European-focused systematic literature review of disease burden

References

• Grundmann O, Yoon SL. Irritable bowel syndrome: epidemiology, diagnosis and treatment: an update for health-care practitioners. J Gastroenterol Hepatol 2010;25:691-9
   PubMed Web of Science ®Google Scholar
• Chang L. Review article: epidemiology and quality of life in functional gastrointestinal disorders. Aliment Pharmacol Ther 2004;20:31-9
   PubMed Web of Science ®Google Scholar
• Quigley EM. Changing face of irritable bowel syndrome. World J Gastroenterol 2006;12:1-5
   PubMed Web of Science ®Google Scholar
• Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012;10:712-21
   PubMed Web of Science ®Google Scholar
• Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. An evidence-based position statement on the management of irritable bowel syndrome. American College of Gastroenterology IBS Task Force. Am J Gastroenterol 2009;104:S1-35
   PubMed Web of Science ®Google Scholar
• Quigley EM, Bytzer P, Jones R, et al. Irritable bowel syndrome: the burden and unmet needs in Europe. Dig Liver Dis 2006;38:717-23
   PubMedGoogle Scholar
• Foxx-Orenstein A. IBS - review and what’s new. MedGenMed 2006;8:20
   PubMedGoogle Scholar
• Park MI, Camilleri M. Is there a role of food allergy in irritable bowel syndrome and functional dyspepsia? A systematic review. Neurogastroenterol Motil 2006;18:595-607
   PubMed Web of Science ®Google Scholar
• Parry SD, Barton JR, Welfare MR. Factors associated with the development of post-infectious functional gastrointestinal diseases: does smoking play a role? Eur J Gastroenterol Hepatol 2005;17:1071-5
   PubMed Web of Science ®Google Scholar
• Simrén M, Månsson A, Langkilde AM, et al. Food-related gastrointestinal symptoms in the irritable bowel syndrome. Digestion 2001;63:108-15
   PubMed Web of Science ®Google Scholar
• Astegiano M, Pellicano R, Sguazzini C, et al. 2008 clinical approach to irritable bowel syndrome. Minerva Gastroenterol Dietol 2008;54:251-7
   PubMedGoogle Scholar
• Cash BD, Chang E, Talley NJ, et al. Fresh perspectives in chronic constipation and other functional bowel disorders. Rev Gastroenterol Disord 2007;7:116-33
   PubMedGoogle Scholar
• Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006;130:1480-91
   PubMed Web of Science ®Google Scholar
• Leong SA, Borghout V, Birnbaum HG, et al. The economic consequences of irritable bowel syndrome: a US employer perspective. Arch Intern Med 2003;163:929-35
   PubMed Web of Science ®Google Scholar
• Reilly MC, Barghout V, McBurney CR, et al. Effect of tegaserod on work and daily activity in irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2005;22:37-80
   Web of Science ®Google Scholar
• Heitkemper MM, Jarrett ME. Update on irritable bowel syndrome and gender differences. Nutr Clin Pract 2008;23:275-83
   PubMed Web of Science ®Google Scholar
• Spiegel BM. The burden of IBS: looking at metrics. Curr Gastroenterol Rep 2009;11:265-9
   PubMedGoogle Scholar
• Harris LA, Crowell MD. Linaclotide, a new direction in the treatment of irritable bowel syndrome and chronic constipation. Curr Opin Mol Ther 2007;9:403-10
   PubMed Web of Science ®Google Scholar
• Roque MV, Camilleri M. Linaclotide, a synthetic guanylate cyclase C agonist for the treatment of functional gastrointestinal disorders associated with constipation. Exp Rev Gastroenterol Hepatol 2011;5:301-10
   PubMed Web of Science ®Google Scholar
• Schey R, Rao SS. Lubiprostone for the treatment of adults with constipation and irritable bowel syndrome. Dig Dis Sci 2011;56:1619-25
   PubMed Web of Science ®Google Scholar
• Spiller RC. Targeting the 5-HT(3) receptor in the treatment of irritable bowel syndrome. Curr Opin Pharmacol 2011;11:68-74
   PubMed Web of Science ®Google Scholar
• Ruepert L, Quartero AO, de Wit NJ, et al. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2011; preprintCD003460
   Google Scholar
• Eurostat. 2012. Total population 2012. http://epp.eurostat.ec.europa.eu/tgm/table.do;jsessionid=9ea7d07e30e987bc1b5a4ae246d9b450c41738acd4d9.e34OaN8Pc3mMc40Lc3aMaNyTaN0Re0?tab=table&plugin=1&language=en&pcode=tps00001. Accessed October 31, 2012
   Google Scholar
• Adeyemo MA, Spiegel BM, Chang L. Meta-analysis: do irritable bowel syndrome symptoms vary between men and women? Aliment Pharmacol Ther 2010;32:738-55
   PubMed Web of Science ®Google Scholar
• Agrawal A, Houghton LA, Reilly B, et al. Bloating and distension in irritable bowel syndrome: the role of gastrointestinal transit. Am J Gastroenterol 2009;104:1998-2004
   PubMed Web of Science ®Google Scholar
• Atkinson W, Lockhart S, Whorwell PJ, et al. Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome. Gastroenterology 2006;130:34-43
   PubMed Web of Science ®Google Scholar
• Bommelaer G, Dorval E, Denis P, et al. Prevalence of irritable bowel syndrome in the French population according to the Rome I criteria. Gastroenterol Clin Biol 2002;26:1118-23
   PubMedGoogle Scholar
• Camilleri M, McKinzie S, Busciglio I, et al. Prospective study of motor, sensory, psychologic, and autonomic functions in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2008;6:772-81
   PubMed Web of Science ®Google Scholar
• Drossman DA. [Characterization of intestinal function and diagnosis of irritable bowel syndrome by surveys and questionnaires]. Gastroenterol Clin Biol 1990;14:37C-41C
   Google Scholar
• Drossman DA, Morris CB, Hu Y, et al. A prospective assessment of bowel habit in irritable bowel syndrome in women: defining an alternator. Gastroenterology 2005;128:580-9
   PubMed Web of Science ®Google Scholar
• Drossman DA. Introduction. The Rome Foundation and Rome III. Neurogastroenterol Motil 2007;19:783-6
   PubMed Web of Science ®Google Scholar
• Garrigues V, Mearin F, Badia X, et al. Change over time of bowel habit in irritable bowel syndrome: a prospective, observational, 1-year follow-up study (RITMO study). Aliment Pharmacol Ther 2007;25:323-32
   PubMed Web of Science ®Google Scholar
• Gunnarsson J, Simren M. Efficient diagnosis of suspected functional bowel disorders. Nat Clin Pract Gastroenterol Hepatol 2008;5:498-507
   PubMedGoogle Scholar
• Herman J, Pokkunuri V, Braham L, et al. Gender distribution in irritable bowel syndrome is proportional to the severity of constipation relative to diarrhea. Gend Med 2010;7:240-6
   PubMedGoogle Scholar
• Khan I, Hassan M, Rahman S. Frequency of organic pathologies in patients with irritable bowel syndrome. JPMI 2009;23:341-6
   Google Scholar
• Khan S, Chang L. Diagnosis and management of IBS. Nat Rev Gastroenterol Hepatol 2010;7:565-81
   PubMed Web of Science ®Google Scholar
• Kruis W, Thieme C, Weinzierl M, et al. A diagnostic score for the irritable bowel syndrome. Its value in the exclusion of organic disease. Gastroenterology 1984;87:1-7
   PubMed Web of Science ®Google Scholar
• Mann NS, Limoges-Gonzales M. The prevalence of small intestinal bacterial vergrowth in irritable bowel syndrome. Hepatogastroenterology 2009;56:718-21
   PubMedGoogle Scholar
• Manning AP, Thompson WG, Heaton KW, et al. Towards positive diagnosis of the irritable bowel. Br Med J 1978;2:653-4
   PubMed Web of Science ®Google Scholar
• Mearin F, Baro E, Roset M, et al. Clinical patterns over time in irritable bowel syndrome: symptom instability and severity variability. Am J Gastroenterol 2004;99:113-21
   PubMed Web of Science ®Google Scholar
• Naliboff BD, Berman S, Suyenobu B, et al. Longitudinal change in perceptual and brain activation response to visceral stimuli in irritable bowel syndrome patients. Gastroenterology 2006;131:352-65
   PubMed Web of Science ®Google Scholar
• Palsson OS, Drossman DA. Psychiatric and psychological dysfunction in irritable bowel syndrome and the role of psychological treatments. Gastroenterol Clin North Am 2005;34:281-303
   PubMed Web of Science ®Google Scholar
• Penny KI, Smith GD, Ramsay D, et al. An examination of subgroup classification in irritable bowel syndrome patients over time: a prospective study. Int J Nurs Stud 2008;45:1715-20
   PubMed Web of Science ®Google Scholar
• Sadik R, Bjornsson E, Simren M. The relationship between symptoms, body mass index, gastrointestinal transit and stool frequency in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 2010;22:102-8
   PubMed Web of Science ®Google Scholar
• Sperber AD, Shvartzman P, Friger M, et al. A comparative reappraisal of the Rome II and Rome III diagnostic criteria: are we getting closer to the ‘true' prevalence of irritable bowel syndrome? Eur J Gastroenterol Hepatol 2007;19:441-7
   PubMed Web of Science ®Google Scholar
• Spiegel BM, Farid M, Esrailian E, et al. Is irritable bowel syndrome a diagnosis of exclusion?: a survey of primary care providers, gastroenterologists, and IBS experts. Am J Gastroenterol 2010;105:848-58
   PubMed Web of Science ®Google Scholar
• Steens J, Van Der Schaar PJ, Penning C, et al. Compliance, tone and sensitivity of the rectum in different subtypes of irritable bowel syndrome. Neurogastroenterol Motil 2002;14:241-7
   PubMed Web of Science ®Google Scholar
• Talley NJ, Phillips SF, Melton LJ, et al. Diagnostic value of the Manning criteria in irritable bowel syndrome. Gut 1990;31:77-81
   PubMed Web of Science ®Google Scholar
• Talley NJ, Zinsmeister AR, Melton LJ, III. Irritable bowel syndrome in a community: symptom subgroups, risk factors, and health care utilization. Am J Epidemiol 1995;142:76-83
   PubMed Web of Science ®Google Scholar
• Talley NJ, Li Z. Helicobacter pylori: testing and treatment. Expert Rev Gastroenterol Hepatol 2007;1:71-9
   PubMedGoogle Scholar
• Thompson WG. The road to Rome. Gut 1999;45(2 Suppl):II80
   PubMed Web of Science ®Google Scholar
• Whitehead WE, Palsson OS, Feld AD, et al. Utility of red flag symptom exclusions in the diagnosis of irritable bowel syndrome. Aliment Pharmacol Ther 2006;24:137-46
   PubMed Web of Science ®Google Scholar
• Zar S, Benson MJ, Kumar D. Rectal afferent hypersensitivity and compliance in irritable bowel syndrome: differences between diarrhoea-predominant and constipation-predominant subgroups. Eur J Gastroenterol Hepatol 2006;18:151-8
   PubMed Web of Science ®Google Scholar
• Zhan L, Zhou D, Xu GM, et al. Study on functional constipation and constipation-predominant irritable bowel syndrome by using the colonic transit test and anorectal manometry. Chin J Dig Dis 2002;3:128-31
   Google Scholar
• Wilson S, Roberts L, Roalfe A, et al. Prevalence of irritable bowel syndrome: a community survey. Br J Gen Pract 2004;54:495-502
   PubMed Web of Science ®Google Scholar
• Mearin F, Balboa A, Badia X, et al. Irritable bowel syndrome subtypes according to bowel habit: revisiting the alternating subtype. Eur J Gastroenterol Hepatol 2003;15:16-72
   Web of Science ®Google Scholar
• Farnam A, Somi MH, Sarami F, et al. Personality factors and profiles in variants of irritable bowel syndrome. World J Gastroenterol 2007;13:6414-8
   PubMed Web of Science ®Google Scholar
• Hertig VL, Cain KC, Jarrett ME, et al. Daily stress and gastrointestinal symptoms in women with irritable bowel syndrome. Nurs Res 2007;56:399-406
   Google Scholar
• Tillisch K, Labus JS, Naliboff BD, et al. Characterization of the alternating bowel habit subtype in patients with irritable bowel syndrome. Am J Gastroenterol 2005;100:896-904
   PubMed Web of Science ®Google Scholar
• Camilleri M, Andrews CN, Bharucha AE, et al. Alterations in expression of p11 and SERT in mucosal biopsy specimens of patients with irritable bowel syndrome. Gastroenterology 2007;132:17-25
   PubMed Web of Science ®Google Scholar
• Amouretti M, Le Pen C, Gaudin AF, et al. Impact of irritable bowel syndrome (IBS) on health-related quality of life (HRQOL). Gastroenterol Clin Biol 2006;30:241-6
   PubMedGoogle Scholar
• Cain KC, Headstrom P, Jarrett ME, et al. Abdominal pain impacts quality of life in women with irritable bowel syndrome. Am J Gastroenterol 2006;101:124-32
   PubMed Web of Science ®Google Scholar
• Coffin B, Dapoigny M, Cloarec D, et al. Relationship between severity of symptoms and quality of life in 858 patients with irritable bowel syndrome. Gastroenterol Clin Biol 2004;28:11-15
   PubMedGoogle Scholar
• Drossman DA, Chey WD, Johanson JF, et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome - results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther 2009;29:329-41
   PubMed Web of Science ®Google Scholar
• Ducrotte P, Dapoigny M, Bonaz B, et al. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial. Aliment Pharmacol Ther 2005;21:435-44
   PubMed Web of Science ®Google Scholar
• Eriksson EM, Andrén KI, Eriksson HT, et al. Irritable bowel syndrome subtypes differ in body awareness, psychological symptoms and biochemical stress markers. World J Gastroenterol 2008;14:4889-96
   PubMed Web of Science ®Google Scholar
• Guyonnet D, Chassany O, Ducrotte P, et al. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther 2007;26:475-86
   PubMed Web of Science ®Google Scholar
• Hawkes ND, Rhodes J, Evans BK, et al. Naloxone treatment for irritable bowel syndrome – a randomized controlled trial with an oral formulation. Aliment Pharmacol Ther 2002;16:1649-54
   PubMed Web of Science ®Google Scholar
• Johanson JF, Drossman DA, Panas R, et al. Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2008;27:685-96
   PubMed Web of Science ®Google Scholar
• Johnston JM, Kurtz CB, Macdougall JE, et al. Linaclotide improves abdominal pain and bowel habits in a Phase IIb study of patients with irritable bowel syndrome with constipation. Gastroenterology 2010;139:1877-86
   PubMed Web of Science ®Google Scholar
• Lembo AJ, Cremonini F, Meyers N, et al. Clinical trial: renzapride treatment of women with irritable bowel syndrome and constipation - a double-blind, randomized, placebo-controlled, study. Aliment Pharmacol Ther 2010;31:979-90
   PubMed Web of Science ®Google Scholar
• Muscatello MR, Bruno A, Pandolfo G, et al. Depression, anxiety and anger in subtypes of irritable bowel syndrome patients. J Clin Psychol Med Settings 2010;17:64-70
   PubMed Web of Science ®Google Scholar
• Si JM, Wang LJ, Chen SJ, et al. Irritable bowel syndrome consulters in Zhejiang province: the symptoms pattern, predominant bowel habit subgroups and quality of life. World J Gastroenterol 2004;10:1059-64
   PubMed Web of Science ®Google Scholar
• Simrén M, Abrahamsson H, Björnsson ES. An exaggerated sensory component of the gastrocolonic response in patients with irritable bowel syndrome. Gut 2001;48:20-7
   PubMed Web of Science ®Google Scholar
• Spiegel B, Camilleri M, Bolus R, et al. Psychometric evaluation of patient-reported outcomes in irritable bowel syndrome randomized controlled trials: a Rome Foundation report. Gastroenterology 2009;137:1944-53.e1–3
   PubMed Web of Science ®Google Scholar
• Spiegel B, Harris L, Lucak S, et al. Developing valid and reliable health utilities in irritable bowel syndrome: results from the IBS PROOF Cohort. Am J Gastroenterol 2009;104:1984-91
   PubMed Web of Science ®Google Scholar
• Tack J, Müller-Lissner S, Bytzer P, et al. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation. Gut 2005;54:1707-13
   PubMed Web of Science ®Google Scholar
• Zhao Y, Zou D, Wang R, et al. Dyspepsia and irritable bowel syndrome in China: a population-based endoscopy study of prevalence and impact. Aliment Pharmacol Ther 2010;32:562-72
   PubMed Web of Science ®Google Scholar
• Maxion-Bergemann S, Thielecke F, Abel F, et al. Costs of irritable bowel syndrome in the UK and US. Pharmacoeconomics 2006;24:21-37
   PubMed Web of Science ®Google Scholar
• Le Pen C, Ruszniewski P, Gaudin AF, et al. The burden cost of French patients suffering from irritable bowel syndrome. Scand J Gastroenterol 2004;39:336-43
   PubMed Web of Science ®Google Scholar
• Jones J, Boorman J, Cann P, et al. British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome. Gut 2000;47(2 Suppl):ii1-19
   PubMed Web of Science ®Google Scholar
• National Collaborating Centre for Nursing and Supportive Care, on behalf of NICE, 2008. Clinical practice guideline. Irritable bowel syndrome in adults: diagnosis and management of irritable bowel syndrome in primary care. www.ncbi.nlm.nih.gov/books/NBK51953. Accessed July 24, 2012
   Google Scholar
• Spiller R, Aziz Q, Creed F, et al. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 2007;56:1770-98
   PubMed Web of Science ®Google Scholar
• Thompson WG, Hungin AP, Neri M, et al. The management of irritable bowel syndrome: a European, primary and secondary care collaboration. Eur J Gastroenterol Hepatol 2001;13:933-9
   PubMed Web of Science ®Google Scholar
• World Gastroenterology Organisation. Irritable bowel syndrome: a global perspective. Milwaukee, WI, USA. 2009. http://www.worldgastroenterology.org/assets/downloads/en/pdf/guidelines/20_irritable_bowel_syndrome.pdf. Accessed July 24 2012
   Google Scholar
• Tort S, Balboa A, Marzo M, et al. [Clinical practice guideline for irritable bowel syndrome]. Gastroenterol Hepatol 2006;29:467-521
   PubMedGoogle Scholar
• Layer P, Andresen V, Pehl C, et al. [Irritable bowel syndrome: German consensus guidelines on definition, pathophysiology and management]. Z Gastroenterol 2011;49:237-93
   PubMed Web of Science ®Google Scholar
• Hawrelak JA, Myers SP. Effects of two natural medicine formulations on irritable bowel syndrome symptoms: a pilot study. J Altern Complement Med 2010;16:1065-71
   PubMed Web of Science ®Google Scholar
• Sallon S, Ben-Arye E, Davidson R, et al. A novel treatment for constipation-predominant irritable bowel syndrome using Padma Lax, a Tibetan herbal formula. Digestion 2002;65:161-71
   PubMed Web of Science ®Google Scholar
• Parisi GC, Zilli M, Miani MP, et al. High-fiber diet supplementation in patients with irritable bowel syndrome (IBS): a multicenter, randomized, open trial comparison between wheat bran diet and partially hydrolyzed guar gum (PHGG). Dig Dis Sci 2002;47:1697-704
   PubMedGoogle Scholar
• Tarpila S, Tarpila A, Grohn P, et al. Efficacy of ground flaxseed on constipation in patients with irritable bowel syndrome. Curr Top Nutraceutical Res 2004;2:119-25
   Google Scholar
• Agrawal A, Houghton LA, Morris J, et al. Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2009;29:104-14
   PubMed Web of Science ®Google Scholar
• Colecchia A, Vestito A, La Rocca A, et al. Effect of a symbiotic preparation on the clinical manifestations of irritable bowel syndrome, constipation-variant. Results of an open, uncontrolled multicenter study. Minerva Gastroenterol Dietol 2006;52:349-58
   PubMedGoogle Scholar
• Dughera L, Elia C, Navino M, et al. Effects of symbiotic preparations on constipated irritable bowel syndrome symptoms. Acta Biomed 2007;78:111-6
   PubMedGoogle Scholar
• Martens U, Enck P, Zieseniss E. Probiotic treatment of irritable bowel syndrome in children. Ger Med Sci 2010;8:Doc07
   PubMedGoogle Scholar
• Vahedi H, Merat S, Rashidioon A, et al. The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study. Aliment Pharmacol Ther 2005;22:381-5
   PubMed Web of Science ®Google Scholar
• Camilleri M, McKinzie S, Fox J, et al. Effect of renzapride on transit in constipation-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2004;2:895-904
   PubMed Web of Science ®Google Scholar
• Chey WD, Paré P, Viegas A, et al. Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial. Am J Gastroenterol 2008;103:1217-25
   PubMed Web of Science ®Google Scholar
• Di Stefano M, Miceli E, Mazzocchi S, et al. Effect of tegaserod on recto-sigmoid tonic and phasic activity in constipation-predominant irritable bowel syndrome. Am J Gastroenterol 2007;102:1720-6
   PubMed Web of Science ®Google Scholar
• Fisher RS, Thistle J, Lembo A, et al. Tegaserod does not alter fasting or meal-induced biliary tract motility. Am J Gastroenterol 2004;99:1342-9
   PubMed Web of Science ®Google Scholar
• Foxx-Orenstein AE, Camilleri M, Szarka LA, et al. Does co-administration of a non-selective opiate antagonist enhance acceleration of transit by a 5-HT4 agonist in constipation-predominant irritable bowel syndrome? A randomized controlled trial. Neurogastroenterol Motil 2007;19:821-30
   PubMed Web of Science ®Google Scholar
• George AM, Meyers NL, Hickling RI. Clinical trial: renzapride therapy for constipation-predominant irritable bowel syndrome - multicentre, randomized, placebo-controlled, double-blind study in primary healthcare setting. Aliment Pharmacol Ther 2008;27:830-7
   PubMed Web of Science ®Google Scholar
• Harish K, Hazeena K, Thomas V, et al. Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome. J Gastroenterol Hepatol 2007;22:1183-9
   PubMed Web of Science ®Google Scholar
• Khoshoo V, Armstead C, Landry L. Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome. Aliment Pharmacol Ther 2006;23:191-6
   PubMed Web of Science ®Google Scholar
• Layer P, Keller J, Mueller-Lissner S, et al. Tegaserod: long-term treatment for irritable bowel syndrome patients with constipation in primary care. Digestion 2005;71:238-44
   PubMed Web of Science ®Google Scholar
• Li Y, Nie Y, Xie J, et al. The association of serotonin transporter genetic polymorphisms and irritable bowel syndrome and its influence on tegaserod treatment in Chinese patients. Dig Dis Sci 2007;52:2942-9
   PubMed Web of Science ®Google Scholar
• Müller-Lissner S, Holtmann G, Rueegg P, et al. Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2005;21:11-20
   PubMed Web of Science ®Google Scholar
• Novick J, Miner P, Krause R, et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002;16:1877-88
   PubMed Web of Science ®Google Scholar
• Prather CM, Camilleri M, Zinsmeister AR, et al. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000;118:463-8
   PubMed Web of Science ®Google Scholar
• Sabaté JM, Bouhassira D, Poupardin C, et al. Sensory signalling effects of tegaserod in patients with irritable bowel syndrome with constipation. Neurogastroenterol Motil 2008;20:134-41
   PubMed Web of Science ®Google Scholar
• Shah SH, Jafri SW, Gul M, et al. Efficacy and tolerability of tegaserod in constipation dominant irritable bowel syndrome. J Coll Physicians Surg Pak 2004;14:21-4
   PubMedGoogle Scholar
• Tack J, Middleton SJ, Horne MC, et al. Pilot study of the efficacy of renzapride on gastrointestinal motility and symptoms in patients with constipation-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2006;23:1655-65
   PubMed Web of Science ®Google Scholar
• Tougas G, Snape WJ Jr., Otten MH, et al. Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2002;16:1701-8
   PubMed Web of Science ®Google Scholar
• Ziegenhagen DJ, Kruis W. Cisapride treatment of constipation-predominant irritable bowel syndrome is not superior to placebo. J Gastroenterol Hepatol 2004;19:744-9
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Public Health Advisory: Tegaserod maleate (marketed as Zelnorm). Silver Spring, MD, USA. 2007. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm051284.htm. Accessed July 20, 2012
   Google Scholar
• Andresen V, Camilleri M, Busciglio IA, et al. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology 2007;133:761-8
   PubMed Web of Science ®Google Scholar
• Ford AC. Overlap among the functional gastrointestinal disorders. Am J Gastroenterol 2010;105:2512
   PubMed Web of Science ®Google Scholar
• Halder SL, Locke GR, III, Schleck CD, et al. Natural history of functional gastrointestinal disorders: a 12-year longitudinal population-based study. Gastroenterology 2007;133:799-807
   PubMed Web of Science ®Google Scholar
• Wong RK, Palsson OS, Turner MJ, et al. Inability of the Rome III criteria to distinguish functional constipation from constipation-subtype irritable bowel syndrome. Am J Gastroenterol 2010;105:2228-34
   PubMed Web of Science ®Google Scholar
• Rome Foundation. Rome III diagnostic criteria for functional gastrointestinal disorders. Raleigh, NC, USA. 2012. http://www.romecriteria.org/assets/pdf/19_RomeIII_apA_885-898.pdf. Accessed December 13, 2012
   Google Scholar
• Bloom MA, Barghout V, Kahler KH, et al. Budget impact of tegaserod on a managed care organization formulary. Am J Manag Care 2005;11:S27-S34
   Web of Science ®Google Scholar